The Healthcare Sector is About More Than Just COVID

By Patricia Miller


In this article

  • Loading...
  • Want to see what you should be buying? Check out our top picks.

Our 'Key Themes For 2022' is designed to help you identify and capitalise on the areas to watch out for. Here we have healthcare.

Investing in Healthcare

Looking for more key themes for 2022? Download our free report.

We keep hearing the same stories of how COVID-19 is impacting our lives on a day-to-day basis. However, the pandemic has resulted in a few exciting developments for the healthcare industry, which you would do well to familiarize yourself with.

COVID-19 Is Still Here

The healthcare sector has been ever-present this past year, with individual companies making headlines for their direct involvement in dealing with the pandemic. We've also seen significant breakthroughs, with multiple vaccines being developed and distributed. This has allowed the public to return to a level of normal during the summer and autumn.

Could we finally forget COVID-19 once and for all and move on for good? At the moment, the answer is a resounding no.

In recent weeks, we've seen a new variant (Omicron) in South Africa. Little is known, but according to the World Health Organization (WHO), preliminary data suggests increasing hospitalization rates. As this news came out, we saw most vaccine maker stocks shoot up. 

Moderna's (NASDAQ: MRNA) stock opened at $370.33 (£277.58) per share before settling at $359.42 by 15:00 UTC, representing a 9% gain on the day.

Similarly, BioNTech (NASDAQ: BNTX) saw its stock open at $369.50 before settling at $360.79, a 3.5% gain from its previous close.

The stocks that saw the most significant upward movement all have one thing in common: their vaccine products can be quickly edited to address the Omicron variant and future mutations, according to the companies' executives. 

As the extensive pharma stocks focus on COVID-19, this may give other stocks opportunities to develop revolutionary products in the healthcare industry and potentially gain some market share.

Key Trends

In 2021 biotech has gotten bigger! We're seeing it implemented in the healthcare industry through the likes of Crispr Therapeutics AG (NASDAQ: CRSP) using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology allowing precise, direct changes to genomic DNA.

CRISPR gene-editing technology system, RNA can be engineered to eliminate or edit a gene. This technology is being utilized more widely by other Big Pharmaceutical companies such as Moderna and BioNTech (NASDAQ: BNTX), who are pioneering their mRNA breakthrough in killing cancer through immunotherapy. Genome sequencing can detect a propensity to a specific type of cancer or autoimmune disease. The genome sequencing company holding the data will guide the patient to a suitable therapy or treatment plan.

The advent of 3D printing technology is also leaving its mark in specialties such as orthopedics, pediatrics, radiology and oncology, and cardiothoracic and vascular surgery.

Doctors, hospitals and researchers around the world are using 3D printing for the following:

  • Preoperative planning and customized surgery

  • Medical devices and surgical instruments

  • Molds, prostheses and customizable implants

  • 3D digital dentistry and drug administration

The advances in 3D-printing technology will attract more customized care and high-precision medical instruments. At the same time, 3D printing is expected to impact other medical specialties such as ophthalmology, regenerative medicine and bio-printing.

Some of the most prominent pioneers in this industry are Organovo Holdings Inc (NASDAQ: ONVO) and EnvisionTEC, owned by Desktop Metal Inc (NYSE: DM). Although year-to-date, its share price is down more than 60%. This could be an opportunity to purchase the stock on the cheap.

Will they, or won't they?

While some states in the USA have legalized cannabis for recreational purposes, the jury is still out on the widespread adoption of psychedelic drugs for medical use, CBD oils and pills have been legal for some time now for medical use, and it's becoming the drug of choice for consumers to manage chronic pain illnesses.

In the last few years, psychedelics have come a long way since their '70s hippy days. There have been studies to support the case that Psychedelics could alleviate issues such as PTSD, depression and addiction. Studies are still ongoing and when it will be legalized is not certain. Still, clinical trials have started and suggested micro-dosing is seen as a way to manage side effects like hallucinations.

What should Investors be looking out for?

The healthcare industry is expanding and becoming interrelated with other parts of the market. And this doesn't look like it'll be changing moving forward.

In 2022, there are three main ways to look at the healthcare sector:

  • Big Pharma

  • The introduction of Biotech

  • The emergence of Alternative medicines like marijuana and psychedelics

The stocks in each of these sectors carry their own risks and rewards, but all have the potential to really pop off in 2022.

Big Pharma

COVID-19 is still a buzzword, which is one of the main reasons we are seeing vaccine makers such as Pfizer (NYSE: PFE) reach all-time highs, trading at around $55 with year-to-date returns of 47%. Even with a P/E ratio of 16.11, we see the valuation is not as high as the rest of the S&P500, at 28.59.

They also pay a dividend of 2.87, meaning more conservative investors who are afraid the market could turn are somewhat protected. We also see similar trends in the other stocks in this space, like GlaxoSmithKline (NYSE: GSK) and AstraZeneca (NYSE: AZN). These have reached all-time highs this past year and also paid a 2% or more dividend.

However, if COVID-19 finally passes us by in 2022, could these stocks continue their growth?


The fast growth in tech in recent years appears to be accelerating further with new innovations, and biotech companies seem to benefit the most.

CRISPR Therapeutics is the highest profile and obvious example. However, lesser-known companies such as Intellia Therapeutics (NASDAQ: NTLA) have shown the first clinical proof of support for delivering CRISPR genome editing via intravenous injection in humans, which saw their share price skyrocket over 100%, with current YTD returns at 82%. The study being done is alongside Regeneron, which also has YTD returns of 31.14%.

This industry's growth has attracted Jeff Bezos's attention, who is reportedly funding the private company Altos Labs, an age-reversal biotech start-up. It has raised at least $270m.

Alternative medicine:

A big opportunity looks like it is presenting itself in the medical cannabis and psychedelics sector. As mentioned above, there are studies supporting the medical use of these products, which in some cases, perform better than traditional medicine. These studies will likely accelerate the push for legalization, with President Biden looking like he will be more lenient than the Trump administration.

However, the stocks in this space have taken a big hit in the past year. YTD's share price decline is in the double digits, with stocks such as Tryp Therapeutics (CNSX: TRYP) down more than 60%. Some of the more high-profile stocks, such as Compass Pathways (NASDAQ: CMPS) and ATAI Life Sciences (NASDAQ: ATAI), backed by ex-PayPal founder Peter Thiel are down 30% to 50%, respectively.

If 2022 sees wider acceptance and legalization, these stocks are in pole position for a big pump as a whole new sector will be created in the healthcare industry.

As 2022 is just around the corner, the healthcare industry doesn't look like it's slowing down anytime soon. The new development in COVID-19 is forcing companies to be agile and adapt their vaccines. The Biotech industry is seeing significant breakthroughs that could develop a new way of treating major illnesses and diseases. And mental health looks like it may have treatment that works.

2022 looks like it could be another exciting year for the industry.

Want to know more about our other key themes for 2022? Download our exclusive free report.

Explore more on these topics:



This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Patricia Miller does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.

Patricia Miller has not been paid to produce this piece by the company or companies mentioned above.

Digitonic Ltd, the owner of, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of, has not been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter